AstraZeneca/Amgen’s Phase III tezepelumab potential to expand to noneosinopilic asthma patients backed by early data and MOA but caution remains

Tezepelumab’s overall efficacy profile was impressive in a Phase II study. Credit: Shutterstock + Orawan Pattarawimonchai.



  • tezepelumab